TPWA
SMMT icon

Twin Peaks Wealth Advisors’s Summit Therapeutics SMMT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228 Buy
+12
New +$194 ﹤0.01% 2153
2025
Q3 		– Sell
-1
Closed -$26 – 1804
2025
Q2 		$26 Buy
+1
New +$23 ﹤0.01% 2235

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Twin Peaks Wealth Advisors's SMMT Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 12 shares worth $228. The stake represents ﹤0.01% of the portfolio and ranks #2153 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in SMMT as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in SMMT in Q2 2025 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Twin Peaks Wealth Advisors held 12 shares of Summit Therapeutics worth $228 as of Q1 2026.
  • Summit Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2153 holding.
  • Twin Peaks Wealth Advisors first reported a position in Summit Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.